A citation-based method for searching scientific literature

Eran Hodis, Ian R Watson, Gregory V Kryukov, Stefan T Arold, Marcin Imielinski, Jean-Philippe Theurillat, Elizabeth Nickerson, Daniel Auclair, Liren Li, Chelsea Place, Daniel Dicara, Alex H Ramos, Michael S Lawrence, Kristian Cibulskis, Andrey Sivachenko, Douglas Voet, Gordon Saksena, Nicolas Stransky, Robert C Onofrio, Wendy Winckler, Kristin Ardlie, Nikhil Wagle, Jennifer Wargo, Kelly Chong, Donald L Morton, Katherine Stemke-Hale, Guo Chen, Michael Noble, Matthew Meyerson, John E Ladbury, Michael A Davies, Jeffrey E Gershenwald, Stephan N Wagner, Dave S B Hoon, Dirk Schadendorf, Eric S Lander, Stacey B Gabriel, Gad Getz, Levi A Garraway, Lynda Chin. Cell 2012
Times Cited: 1533







List of co-cited articles
669 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
Michael Krauthammer, Yong Kong, Byung Hak Ha, Perry Evans, Antonella Bacchiocchi, James P McCusker, Elaine Cheng, Matthew J Davis, Gerald Goh, Murim Choi,[...]. Nat Genet 2012
753
30

Whole-genome landscapes of major melanoma subtypes.
Nicholas K Hayward, James S Wilmott, Nicola Waddell, Peter A Johansson, Matthew A Field, Katia Nones, Ann-Marie Patch, Hojabr Kakavand, Ludmil B Alexandrov, Hazel Burke,[...]. Nature 2017
477
18

Mutations of the BRAF gene in human cancer.
Helen Davies, Graham R Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Sheila Clegg, Jon Teague, Hayley Woffendin, Mathew J Garnett, William Bottomley,[...]. Nature 2002
17

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.
Ethan Cerami, Jianjiong Gao, Ugur Dogrusoz, Benjamin E Gross, Selcuk Onur Sumer, Bülent Arman Aksoy, Anders Jacobsen, Caitlin J Byrne, Michael L Heuer, Erik Larsson,[...]. Cancer Discov 2012
14

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
Eliezer M Van Allen, Nikhil Wagle, Antje Sucker, Daniel J Treacy, Cory M Johannessen, Eva M Goetz, Chelsea S Place, Amaro Taylor-Weiner, Steven Whittaker, Gregory V Kryukov,[...]. Cancer Discov 2014
561
13

The Genetic Evolution of Melanoma from Precursor Lesions.
A Hunter Shain, Iwei Yeh, Ivanka Kovalyshyn, Aravindhan Sriharan, Eric Talevich, Alexander Gagnon, Reinhard Dummer, Jeffrey North, Laura Pincus, Beth Ruben,[...]. N Engl J Med 2015
438
13

TERT promoter mutations in familial and sporadic melanoma.
Susanne Horn, Adina Figl, P Sivaramakrishna Rachakonda, Christine Fischer, Antje Sucker, Andreas Gast, Stephanie Kadel, Iris Moll, Eduardo Nagore, Kari Hemminki,[...]. Science 2013
12

Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.
Michael Krauthammer, Yong Kong, Antonella Bacchiocchi, Perry Evans, Natapol Pornputtapong, Cen Wu, James P McCusker, Shuangge Ma, Elaine Cheng, Robert Straub,[...]. Nat Genet 2015
200
11

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.
Hubing Shi, Willy Hugo, Xiangju Kong, Aayoung Hong, Richard C Koya, Gatien Moriceau, Thinle Chodon, Rongqing Guo, Douglas B Johnson, Kimberly B Dahlman,[...]. Cancer Discov 2014
610
11

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.
Jianjiong Gao, Bülent Arman Aksoy, Ugur Dogrusoz, Gideon Dresdner, Benjamin Gross, S Onur Sumer, Yichao Sun, Anders Jacobsen, Rileen Sinha, Erik Larsson,[...]. Sci Signal 2013
10

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq.
Itay Tirosh, Benjamin Izar, Sanjay M Prakadan, Marc H Wadsworth, Daniel Treacy, John J Trombetta, Asaf Rotem, Christopher Rodman, Christine Lian, George Murphy,[...]. Science 2016
10

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Ramin Nazarian, Hubing Shi, Qi Wang, Xiangju Kong, Richard C Koya, Hane Lee, Zugen Chen, Mi-Kyung Lee, Narsis Attar, Hooman Sazegar,[...]. Nature 2010
10

Melanoma genome sequencing reveals frequent PREX2 mutations.
Michael F Berger, Eran Hodis, Timothy P Heffernan, Yonathan Lissanu Deribe, Michael S Lawrence, Alexei Protopopov, Elena Ivanova, Ian R Watson, Elizabeth Nickerson, Papia Ghosh,[...]. Nature 2012
483
9

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Axel Hauschild, Jean-Jacques Grob, Lev V Demidov, Thomas Jouary, Ralf Gutzmer, Michael Millward, Piotr Rutkowski, Christian U Blank, Wilson H Miller, Eckhart Kaempgen,[...]. Lancet 2012
9

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Paul B Chapman, Axel Hauschild, Caroline Robert, John B Haanen, Paolo Ascierto, James Larkin, Reinhard Dummer, Claus Garbe, Alessandro Testori, Michele Maio,[...]. N Engl J Med 2011
9

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
James Larkin, Paolo A Ascierto, Brigitte Dréno, Victoria Atkinson, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stroyakovskiy, Luc Thomas,[...]. N Engl J Med 2014
9

Distinct sets of genetic alterations in melanoma.
John A Curtin, Jane Fridlyand, Toshiro Kageshita, Hetal N Patel, Klaus J Busam, Heinz Kutzner, Kwang-Hyun Cho, Setsuya Aiba, Eva-Bettina Bröcker, Philip E LeBoit,[...]. N Engl J Med 2005
9


Signatures of mutational processes in human cancer.
Ludmil B Alexandrov, Serena Nik-Zainal, David C Wedge, Samuel A J R Aparicio, Sam Behjati, Andrew V Biankin, Graham R Bignell, Niccolò Bolli, Ake Borg, Anne-Lise Børresen-Dale,[...]. Nature 2013
9

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer,[...]. Lancet Oncol 2018
191
8

Toward Minimal Residual Disease-Directed Therapy in Melanoma.
Florian Rambow, Aljosja Rogiers, Oskar Marin-Bejar, Sara Aibar, Julia Femel, Michael Dewaele, Panagiotis Karras, Daniel Brown, Young Hwan Chang, Maria Debiec-Rychter,[...]. Cell 2018
158
8

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Cory M Johannessen, Jesse S Boehm, So Young Kim, Sapana R Thomas, Leslie Wardwell, Laura A Johnson, Caroline M Emery, Nicolas Stransky, Alexandria P Cogdill, Jordi Barretina,[...]. Nature 2010
8

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Caroline Robert, Jean J Grob, Daniil Stroyakovskiy, Boguslawa Karaszewska, Axel Hauschild, Evgeny Levchenko, Vanna Chiarion Sileni, Jacob Schachter, Claus Garbe, Igor Bondarenko,[...]. N Engl J Med 2019
278
8

High frequency of BRAF mutations in nevi.
Pamela M Pollock, Ursula L Harper, Katherine S Hansen, Laura M Yudt, Mitchell Stark, Christiane M Robbins, Tracy Y Moses, Galen Hostetter, Urs Wagner, John Kakareka,[...]. Nat Genet 2003
8

A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.
Alexander Roesch, Mizuho Fukunaga-Kalabis, Elizabeth C Schmidt, Susan E Zabierowski, Patricia A Brafford, Adina Vultur, Devraj Basu, Phyllis Gimotty, Thomas Vogt, Meenhard Herlyn. Cell 2010
755
8

Highly recurrent TERT promoter mutations in human melanoma.
Franklin W Huang, Eran Hodis, Mary Jue Xu, Gregory V Kryukov, Lynda Chin, Levi A Garraway. Science 2013
8

A comprehensive catalogue of somatic mutations from a human cancer genome.
Erin D Pleasance, R Keira Cheetham, Philip J Stephens, David J McBride, Sean J Humphray, Chris D Greenman, Ignacio Varela, Meng-Lay Lin, Gonzalo R Ordóñez, Graham R Bignell,[...]. Nature 2010
7

COSMIC: the Catalogue Of Somatic Mutations In Cancer.
John G Tate, Sally Bamford, Harry C Jubb, Zbyslaw Sondka, David M Beare, Nidhi Bindal, Harry Boutselakis, Charlotte G Cole, Celestino Creatore, Elisabeth Dawson,[...]. Nucleic Acids Res 2019
833
7

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer,[...]. Lancet Oncol 2018
292
7

NRAS mutation status is an independent prognostic factor in metastatic melanoma.
John A Jakob, Roland L Bassett, Chaan S Ng, Jonathan L Curry, Richard W Joseph, Gladys C Alvarado, Michelle L Rohlfs, Jessie Richard, Jeffrey E Gershenwald, Kevin B Kim,[...]. Cancer 2012
433
7

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.
Hubing Shi, Gatien Moriceau, Xiangju Kong, Mi-Kyung Lee, Hane Lee, Richard C Koya, Charles Ng, Thinle Chodon, Richard A Scolyer, Kimberly B Dahlman,[...]. Nat Commun 2012
456
7

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
Willy Hugo, Jesse M Zaretsky, Lu Sun, Chunying Song, Blanca Homet Moreno, Siwen Hu-Lieskovan, Beata Berent-Maoz, Jia Pang, Bartosz Chmielowski, Grace Cherry,[...]. Cell 2016
7

Mutational heterogeneity in cancer and the search for new cancer-associated genes.
Michael S Lawrence, Petar Stojanov, Paz Polak, Gregory V Kryukov, Kristian Cibulskis, Andrey Sivachenko, Scott L Carter, Chip Stewart, Craig H Mermel, Steven A Roberts,[...]. Nature 2013
7

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.
Helen Rizos, Alexander M Menzies, Gulietta M Pupo, Matteo S Carlino, Carina Fung, Jessica Hyman, Lauren E Haydu, Branka Mijatov, Therese M Becker, Suzanah C Boyd,[...]. Clin Cancer Res 2014
296
7

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
Eliezer M Van Allen, Diana Miao, Bastian Schilling, Sachet A Shukla, Christian Blank, Lisa Zimmer, Antje Sucker, Uwe Hillen, Marnix H Geukes Foppen, Simone M Goldinger,[...]. Science 2015
7

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.
Levi A Garraway, Hans R Widlund, Mark A Rubin, Gad Getz, Aaron J Berger, Sridhar Ramaswamy, Rameen Beroukhim, Danny A Milner, Scott R Granter, Jinyan Du,[...]. Nature 2005
7

From melanocytes to melanomas.
A Hunter Shain, Boris C Bastian. Nat Rev Cancer 2016
276
7

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.
Gatien Moriceau, Willy Hugo, Aayoung Hong, Hubing Shi, Xiangju Kong, Clarissa C Yu, Richard C Koya, Ahmed A Samatar, Negar Khanlou, Jonathan Braun,[...]. Cancer Cell 2015
192
7

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
6

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Paolo A Ascierto, Grant A McArthur, Brigitte Dréno, Victoria Atkinson, Gabrielle Liszkay, Anna Maria Di Giacomo, Mario Mandalà, Lev Demidov, Daniil Stroyakovskiy, Luc Thomas,[...]. Lancet Oncol 2016
437
6

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.
Livnat Jerby-Arnon, Parin Shah, Michael S Cuoco, Christopher Rodman, Mei-Ju Su, Johannes C Melms, Rachel Leeson, Abhay Kanodia, Shaolin Mei, Jia-Ren Lin,[...]. Cell 2018
274
6

Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Alexandra Snyder, Vladimir Makarov, Taha Merghoub, Jianda Yuan, Jesse M Zaretsky, Alexis Desrichard, Logan A Walsh, Michael A Postow, Phillip Wong, Teresa S Ho,[...]. N Engl J Med 2014
6

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Ahmet Zehir, Ryma Benayed, Ronak H Shah, Aijazuddin Syed, Sumit Middha, Hyunjae R Kim, Preethi Srinivasan, Jianjiong Gao, Debyani Chakravarty, Sean M Devlin,[...]. Nat Med 2017
6

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Judith Müller, Oscar Krijgsman, Jennifer Tsoi, Lidia Robert, Willy Hugo, Chunying Song, Xiangju Kong, Patricia A Possik, Paulien D M Cornelissen-Steijger, Marnix H Geukes Foppen,[...]. Nat Commun 2014
298
6

Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells.
Alexander Roesch, Adina Vultur, Ivan Bogeski, Huan Wang, Katharina M Zimmermann, David Speicher, Christina Körbel, Matthias W Laschke, Phyllis A Gimotty, Stephan E Philipp,[...]. Cancer Cell 2013
375
6

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean Jacques Grob, C Lance Cowey, Christopher D Lao, Dirk Schadendorf, Reinhard Dummer, Michael Smylie, Piotr Rutkowski,[...]. N Engl J Med 2015
6

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.
Jessie Villanueva, Adina Vultur, John T Lee, Rajasekharan Somasundaram, Mizuho Fukunaga-Kalabis, Angela K Cipolla, Bradley Wubbenhorst, Xiaowei Xu, Phyllis A Gimotty, Damien Kee,[...]. Cancer Cell 2010
894
6

Improved overall survival in melanoma with combined dabrafenib and trametinib.
Caroline Robert, Boguslawa Karaszewska, Jacob Schachter, Piotr Rutkowski, Andrzej Mackiewicz, Daniil Stroiakovski, Michael Lichinitser, Reinhard Dummer, Florent Grange, Laurent Mortier,[...]. N Engl J Med 2015
6

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas, Evgeny Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean Jacques Grob,[...]. N Engl J Med 2014
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.